
    
      Patients who will be allocated in arm A, will receive a single intratumor injection of NBTXR3
      and will receive external beam radiotherapy starting 24hrs after the injection up to
      completion of 5 weeks, 5 days a week of treatment (50Gy, 2Gy/fraction). Then, all patients
      will undergo surgical resection of the tumor 5 weeks later and will be followed for wound
      healing and toxicity assessment. A visit of end of treatment will take place approximately
      3-4 weeks after surgery. Patients will be followed for evaluation of their disease status and
      adverse event until the end of study.
    
  